Te­va suf­fers set­back on in-house asth­ma pro­gram as a PhII study is halt­ed ear­ly due to fu­til­i­ty

Al­though Te­va large­ly makes its mon­ey these days through gener­ic drug sales, the com­pa­ny con­tin­ues to de­vel­op a suite of asth­ma med­i­cines and in­halers for its in-house R&D ef­forts. But one such can­di­date has ap­par­ent­ly hit a speed bump.

Ac­cord­ing to a Mon­day up­date post­ed on clin­i­cal­tri­als.gov, Te­va ter­mi­nat­ed a Phase II asth­ma study ear­ly due to fu­til­i­ty fol­low­ing an in­ter­im analy­sis. The tri­al had been look­ing to eval­u­ate the pro­gram known as TEV-48574 in 65 adults over 16 weeks, re­gard­less if their se­vere asth­ma is trig­gered by al­ler­gens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER